POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine aims to shield transplant patients from Cancer-Causing virus
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tests a vaccine (OSU-2131) designed to help the immune system fight Epstein-Barr virus (EBV), which can cause cancer in people with weakened immunity. The study includes healthy volunteers and patients waiting for a solid organ transplant, who are at higher…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 10:09 UTC
-
Smarter CMV strategy may protect stem cell transplant patients
Disease control OngoingThis study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 10:10 UTC
-
Engineered t cells take on returning B-Cell cancers in early trial
Disease control OngoingThis early-phase study tests a new treatment for adults with B-cell cancers (like lymphoma or leukemia) that returned after prior therapy. Doctors take a patient's own white blood cells, add a gene to help them find and kill cancer cells, and give them back after chemotherapy. Th…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC